SpyBiotech

SpyBiotech

Utilizing unique protein superglue technology to develop vaccines against infectious disease and cancer worldwide

Founded 2017

Oxford, United Kingdom 23 employees Grant Total: $40.59M Biotechnology, Life Sciences

SpyBiotech is a UK-based biotechnology company founded in 2017, which has developed a novel vaccine platform utilizing proprietary protein superglue technology. The company's slogan "Utilizing unique protein superglue technology to develop vaccines against infectious disease and cancer worldwide" highlights its focus on targeting infectious diseases, cancer, and chronic diseases. SpyBiotech specializes in binding antigens to vaccine delivery platforms in a way that minimizes delivery risk and enhances immunogenicity and efficacy. The company's current lead candidate is against human cytomegalovirus (HCMV), with clinical studies planned for this year. Notably, the latest investment of $4.09M in the form of a grant was received on 20 March 2023 from the Bill & Melinda Gates Foundation. This investment signifies confidence in the company's innovative approach and potential to address critical global health challenges. With its cutting-edge technology and promising developments, SpyBiotech is positioned as an impactful player in the biotechnology industry, promising significant advancements in vaccine development and disease treatment.

Funding Stage	Amount	Investors	Lead Investors	Date
Grant	$4.09M	1	Bill & Melinda Gates Foundation	20 Mar 2023
Series A	$32.50M	5	GV, Oxford Science Enterprises +3	10 Feb 2021
Seed Round	£4.00M	2	GV, Oxford Science Enterprises	30 Mar 2017

Funding Stage

Amount

Investors

Lead Investors

Date

Grant

$4.09M

Bill & Melinda Gates Foundation

20 Mar 2023

Series A

$32.50M

GV, Oxford Science Enterprises +3

10 Feb 2021

Seed Round

£4.00M

GV, Oxford Science Enterprises

30 Mar 2017

FAQ About SpyBiotech

Utilizing unique protein superglue technology to develop vaccines against infectious disease and cancer worldwide

SpyBiotech was founded in 2017.

SpyBiotech is headquartered in Oxford, United Kingdom.

SpyBiotech operates in Biotechnology and Life Sciences. Its work centres on Vaccine development, Biotechnology platform, Infectious diseases and Cancer vaccines.

SpyBiotech has approximately 23 employees.

SpyBiotech has completed 3 funding rounds, raising a total of $40.59M. The latest funding stage is Grant.

Top alternatives and competitors to SpyBiotech include Memgen, Inc., Baseimmune, ReNewVax Ltd, T3 Pharmaceuticals AG, Immunomic Therapeutics, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

SpyBiotech and Memgen, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About SpyBiotech

Funding Rounds & Investors (3)

SpyBiotech Alternatives & Competitors

FAQ About SpyBiotech